TrivarX Limited (AU:TRI) has released an update.
TrivarX Limited has reported the successful completion of its Phase 2 SAMDE study, which aims to screen for Major Depressive Episode (cMDE) using its AI-driven algorithm, MEB-001, with high sensitivity and negative predictive values. The promising results are expected to support FDA clearance efforts and the company has also appointed healthcare executive W. Drew Palin to explore commercial opportunities. Additionally, TrivarX has bolstered its financial position with a recent $2.5 million capital raise.
For further insights into AU:TRI stock, check out TipRanks’ Stock Analysis page.
